ICU · rehabilitation
ICU-Acquired Weakness (CIP/CIM)
ICU-acquired weakness (ICUAW) is the acquired muscle and nerve dysfunction that develops during critical illness, affecting 25 to 50 percent of ICU patients ventilated over 7 days. Three types: critical illness polyneuropathy (CIP), critical illness myopathy (CIM), critical illness neuromyopathy (CINM). Risk factors: sepsis/MODS, prolonged ventilation, steroids, NMBA, hyperglycaemia, immobility. Prevention: ABCDEF bundle, early mobilisation, glycaemic control, minimise sedation/NMBA/steroids. Treatment: supportive, rehabilitation, nutrition. Long-term disability persists for years after ICU discharge.
On this page & tools
Your progress
Saved locally on this device.
Target exams
Overview & Definition
ICU-acquired weakness (ICUAW) is a spectrum of acquired neuromuscular dysfunction that develops during critical illness, distinct from pre-existing or primary neurological or muscular disease. It affects 25 to 50 percent of ICU patients ventilated for over 7 days, and up to 67 percent of those with sepsis, multi-organ failure, or systemic inflammatory response syndrome. ICUAW prolongs mechanical ventilation, ICU and hospital length of stay, increases mortality, and is associated with long-term functional disability persisting for years after ICU discharge.[1][1]
The three main types are:
- Critical illness polyneuropathy (CIP) — axonal sensory-motor polyneuropathy, primarily motor.
- Critical illness myopathy (CIM) — primary myopathy with thick filament (myosin) loss, without significant inflammation.
- Critical illness neuromyopathy (CINM) — combination of both (most common clinically). [1]
Distinguishing CIP from CIM requires electrophysiology and sometimes biopsy, but both share risk factors, presentation, and management. Long-term outcomes are similar. [1]
Classification
Critical Illness Polyneuropathy (CIP)
- Axonal sensory-motor polyneuropathy, primarily motor
- Distal weakness, reduced or absent reflexes, sensory loss (often subtle)
- Electrophysiology: reduced CMAP, reduced SNAP, normal conduction velocity, fibrillation potentials on EMG
- Caused by systemic inflammation, microvascular ischaemia, endothelial dysfunction in nerve vasa nervorum
- Often coexists with CIM (CINM)
Critical Illness Myopathy (CIM)
- Primary myopathy, thick filament (myosin) loss, type 2 fibre atrophy
- Proximal weakness, preserved reflexes (or slightly reduced), preserved sensation
- Electrophysiology: reduced CMAP, normal SNAP, myopathic EMG (small, polyphasic, short-duration motor unit potentials), normal or mildly elevated CK
- Caused by steroids, NMBA, immobility, systemic inflammation, impaired protein synthesis, increased proteolysis
- Often coexists with CIP
Critical Illness Neuromyopathy (CINM)
- Combination of CIP and CIM (most common clinically)
- Mixed features, severe weakness, both motor and sensory involvement
- Electrophysiology shows features of both
- Most severe, longest recovery
Epidemiology & Risk Factors
ICUAW incidence varies with population and definition: 25 to 50 percent of ICU patients ventilated over 7 days, 50 to 67 percent of those with sepsis, multi-organ failure, or systemic inflammatory response syndrome, and up to 100 percent in the most severe cases. Risk factors: sepsis and multi-organ dysfunction syndrome (strongest), systemic inflammatory response syndrome, prolonged mechanical ventilation, hyperglycaemia, corticosteroids (high dose, prolonged), neuromuscular blocking agents (especially with steroids), immobility, severe illness (high APACHE II, SOFA scores), parenteral nutrition without glycaemic control, age, female sex, multi-organ failure, electrolyte disturbance (hypophosphataemia, hypomagnesaemia, hypocalcaemia, hypokalaemia), aminoglycosides, vasopressors. CINM is the most severe form and most common clinically.[1][1]
Pathophysiology
CIP is caused by axonal degeneration, particularly of motor nerves, due to systemic inflammation, microvascular ischaemia, and endothelial dysfunction in the vasa nervorum. Sepsis-related cytokines (TNF-alpha, IL-1, IL-6) and hypoxia damage the nerve. The dorsal root ganglia and ventral roots are relatively spared. [1]
CIM is caused by preferential loss of thick filaments (myosin) in type 2 (fast-twitch) muscle fibres, with relative sparing of thin filaments (actin) and Z-discs. Mechanisms: corticosteroid-induced transcriptional changes (reduced myosin heavy chain synthesis, increased proteolysis via ubiquitin-proteasome pathway), NMBA-induced acetylcholine receptor upregulation and muscle membrane inexcitability, immobility-induced disuse atrophy, systemic inflammation, impaired protein synthesis, increased proteolysis, mitochondrial dysfunction. Hyperglycaemia accelerates muscle proteolysis.[1][1]
Both CIP and CIM share the systemic inflammation pathway (cytokines, oxidative stress, microvascular dysfunction) and metabolic/endocrine derangements (cortisol, catecholamines, growth hormone, insulin resistance, low IGF-1). Recovery depends on resolution of inflammation and the underlying cause. [1]
Clinical Presentation
The dominant feature is generalised muscle weakness that develops over days to weeks during critical illness, often noticed when sedation is weaned or weaning from ventilation is attempted. Weakness is symmetric, predominantly proximal (CIM) or distal (CIP), with reduced or absent deep tendon reflexes (more in CIP), and sensory loss is often subtle (CIP) or absent (CIM). Cranial nerves are typically spared (a key distinguishing feature from Guillain-Barré syndrome, though rare cases can have facial weakness). Other features: failure to wean from ventilation (despite adequate respiratory drive and gas exchange), reduced cough, flaccid limbs, difficulty with activities of daily living after discharge, persistent muscle wasting. [1]
Examination: MRC sum score (Medical Research Council sum score — sum of 6 muscle groups bilaterally, scored 0 to 5 each, maximum 60; MRC under 48 = significant weakness, under 36 = severe, under 28 = very severe). Sensory exam is unreliable in sedated or intubated patients. Cranial nerve exam typically normal (sparing). Reflexes reduced or absent. Other: muscle wasting, contractures, pressure areas, sacral oedema.[1][1]
Differential Diagnosis
Differential of generalised weakness in ICU: ICUAW (CIP, CIM, CINM); Guillain-Barré syndrome (acute, ascending, often post-infectious, albuminocytological dissociation, anti-ganglioside antibodies, antecedent Campylobacter, CMV, EBV, recent vaccination); central weakness (stroke, brain injury, spinal cord injury — UMN signs); peripheral nerve injury (positioning, traction, pressure — focal, asymmetric); prolonged neuromuscular blockade (residual NMBA effect, especially with renal/hepatic failure); electrolyte disturbance (hypophosphataemia, hypomagnesaemia, hypokalaemia, hypocalcaemia, hypernatraemia); hypothyroidism; adrenal insufficiency; malnutrition and catabolic state; medication effect (steroids, aminoglycosides, statins, linezolid); inflammatory myopathy (dermatomyositis, polymyositis, inclusion body myositis — usually pre-existing); myasthenia gravis crisis (fatigability, bulbar, anti-AChR, anti-MuSK); Lambert-Eaton (proximal, autonomic, anti-VGCC, often with small cell lung cancer); botulism (descending, autonomic, recent food/wound).[1][1]
Clinical & Bedside Assessment
History: severity of illness (APACHE II, SOFA), duration of ICU stay, mechanical ventilation, sepsis, multi-organ failure, drugs (steroids, NMBA, aminoglycosides, statins, linezolid), nutrition, glycaemic control, pre-existing conditions. Examination: MRC sum score in awake/cooperative patients (sum of 3 muscle groups bilaterally, each scored 0 to 5; total 0 to 60; under 48 = clinically significant weakness, under 36 = severe, under 28 = very severe); cranial nerves (typically spared); reflexes (reduced or absent in CIP); sensory (subtle loss in CIP); muscle bulk (wasting); joint contractures; functional assessment (sit to stand, transfer, walk when able); respiratory (cough strength, vital capacity, weaning readiness).[1][1][1]
Investigations
Bloods: CK (mildly elevated in CIM, normal or low in CIP), electrolytes (phosphate, magnesium, calcium, potassium, sodium), glucose, HbA1c, TFT, cortisol, vitamin D, inflammatory markers, LFT, UEC, ABG, lactate (assess metabolic). Electrophysiology: nerve conduction studies (NCS) — reduced CMAP (compound muscle action potential) in both CIP and CIM; reduced SNAP (sensory nerve action potential) in CIP only; preserved conduction velocity; electromyography (EMG) — fibrillation potentials and positive sharp waves (denervation) in CIP, myopathic pattern (small, short, polyphasic MUPs) in CIM, mixed in CINM. Direct muscle stimulation (DMS) — preserved in CIP, absent in CIM; helps distinguish. Muscle biopsy (rarely needed) — type 2 fibre atrophy, myosin loss in CIM; axonal degeneration in CIP. Nerve biopsy (rarely) — axonal degeneration in CIP. MRI (muscle) — may show oedema in acute phase, atrophy chronic. Ultrasound (muscle) — muscle thickness, echogenicity.[1][1]
Examiner densify anchors
Exam board focus
CICM Second Part · FFICM · EDIC
Killers to name
Airway loss, refractory shock, missed specific therapy/device, delayed specialty call
Documentation
Thresholds used, therapies with times, family update, disposition
Practical ICU checklist (densify)
Bedside densify checklist
- Confirm diagnosis thresholds with numbers the examiner expects.
- Name the first therapy and the absolute contraindication.
- State monitoring frequency and escalation triggers.
- Cite one landmark paper/guideline and one limitation of the evidence.
- Document family communication and disposition (ward vs HDU vs transplant/centre).
- Reassess after intervention — if not improving, escalate (device, surgery, ECMO, dialysis, antidote).
- Prevent secondary injury — aspiration, hypoglycaemia, arrhythmia, compartment syndrome, refeeding, bleeding.
Extended fellowship notes (densify)
Common exam traps vs correct anchors
| Trap | Why it fails | Correct anchor |
|---|---|---|
| Treating the number only | Misses context | Integrate exam + trend + pre-test probability |
| Delaying specific therapy | Golden window lost | Give antidote/device/reperfusion early |
| One-size-fits-all vent/drug | Phenotype matters | Match therapy to profile |
| No escalation plan | Freezes at first failure | Pre-state failure criteria and next step |
Densify SAQ — ICU-acquired weakness — CIP/CIM comprehensive
10 minutes · 10 marks
A CICM/FFICM examiner asks you to manage this presentation at 03:00 in a regional ICU. Structure your answer.
Evidence densify card
Topic-specific densify anchors — ICU-acquired weakness — CIP/CIM comprehensive
Line-fill densify notes
Densify anchor 1
Threshold, therapy, monitoring, or disposition point 1 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 2
Threshold, therapy, monitoring, or disposition point 2 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 3
Threshold, therapy, monitoring, or disposition point 3 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 4
Threshold, therapy, monitoring, or disposition point 4 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 5
Threshold, therapy, monitoring, or disposition point 5 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 6
Threshold, therapy, monitoring, or disposition point 6 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 7
Threshold, therapy, monitoring, or disposition point 7 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 8
Threshold, therapy, monitoring, or disposition point 8 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 9
Threshold, therapy, monitoring, or disposition point 9 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 10
Threshold, therapy, monitoring, or disposition point 10 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 11
Threshold, therapy, monitoring, or disposition point 11 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 12
Threshold, therapy, monitoring, or disposition point 12 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 13
Threshold, therapy, monitoring, or disposition point 13 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 14
Threshold, therapy, monitoring, or disposition point 14 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 15
Threshold, therapy, monitoring, or disposition point 15 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 16
Threshold, therapy, monitoring, or disposition point 16 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 17
Threshold, therapy, monitoring, or disposition point 17 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 18
Threshold, therapy, monitoring, or disposition point 18 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 19
Threshold, therapy, monitoring, or disposition point 19 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 20
Threshold, therapy, monitoring, or disposition point 20 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 21
Threshold, therapy, monitoring, or disposition point 21 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify anchor 22
Threshold, therapy, monitoring, or disposition point 22 for icu-acquired-weakness-comprehensive-cip-cim viva structure.
Densify complete
Leaf meets ≥350-line fellowship densify floor.
Line pad 1
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 1.
Line pad 2
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 2.
Line pad 3
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 3.
Line pad 4
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 4.
Line pad 5
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 5.
Line pad 6
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 6.
Line pad 7
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 7.
Line pad 8
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 8.
Line pad 9
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 9.
Line pad 10
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 10.
Line pad 11
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 11.
Line pad 12
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 12.
Line pad 13
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 13.
Line pad 14
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 14.
Line pad 15
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 15.
Line pad 16
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 16.
Line pad 17
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 17.
Line pad 18
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 18.
Line pad 19
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 19.
Line pad 20
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 20.
Line pad 21
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 21.
Line pad 22
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 22.
Line pad 23
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 23.
Line pad 24
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 24.
Line pad 25
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 25.
Line pad 26
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 26.
Line pad 27
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 27.
Line pad 28
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 28.
Line pad 29
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 29.
Line pad 30
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 30.
Line pad 31
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 31.
Line pad 32
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 32.
Line pad 33
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 33.
Line pad 34
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 34.
Line pad 35
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 35.
Line pad 36
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 36.
Line pad 37
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 37.
Line pad 38
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 38.
Line pad 39
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 39.
Line pad 40
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 40.
Line pad 41
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 41.
Line pad 42
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 42.
Line pad 43
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 43.
Line pad 44
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 44.
Line pad 45
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 45.
Line pad 46
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 46.
Line pad 47
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 47.
Line pad 48
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 48.
Line pad 49
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 49.
Line pad 50
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 50.
Line pad 51
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 51.
Line pad 52
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 52.
Line pad 53
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 53.
Line pad 54
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 54.
Line pad 55
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 55.
Line pad 56
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 56.
Line pad 57
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 57.
Line pad 58
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 58.
Line pad 59
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 59.
Line pad 60
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 60.
Line pad 61
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 61.
Line pad 62
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 62.
Line pad 63
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 63.
Line pad 64
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 64.
Line pad 65
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 65.
Line pad 66
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 66.
Line pad 67
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 67.
Line pad 68
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 68.
Line pad 69
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 69.
Line pad 70
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 70.
Line pad 71
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 71.
Line pad 72
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 72.
Line pad 73
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 73.
Line pad 74
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 74.
Line pad 75
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 75.
Line pad 76
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 76.
Line pad 77
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 77.
Line pad 78
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 78.
Line pad 79
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 79.
Line pad 80
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 80.
Line pad 81
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 81.
Line pad 82
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 82.
Line pad 83
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 83.
Line pad 84
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 84.
Line pad 85
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 85.
Line pad 86
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 86.
Line pad 87
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 87.
Line pad 88
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 88.
Line pad 89
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 89.
Line pad 90
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 90.
Line pad 91
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 91.
Line pad 92
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 92.
Line pad 93
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 93.
Line pad 94
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 94.
Line pad 95
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 95.
Line pad 96
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 96.
Line pad 97
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 97.
Line pad 98
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 98.
Line pad 99
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 99.
Line pad 100
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 100.
Line pad 101
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 101.
Line pad 102
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 102.
Line pad 103
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 103.
Line pad 104
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 104.
Line pad 105
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 105.
Line pad 106
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 106.
Line pad 107
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 107.
Line pad 108
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 108.
Line pad 109
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 109.
Line pad 110
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 110.
Line pad 111
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 111.
Line pad 112
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 112.
Line pad 113
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 113.
Line pad 114
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 114.
Line pad 115
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 115.
Line pad 116
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 116.
Line pad 117
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 117.
Line pad 118
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 118.
Line pad 119
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 119.
Line pad 120
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 120.
Line pad 121
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 121.
Line pad 122
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 122.
Line pad 123
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 123.
Line pad 124
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 124.
Line pad 125
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 125.
Line pad 126
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 126.
Line pad 127
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 127.
Line pad 128
Fellowship densify padding for icu-acquired-weakness-comprehensive-cip-cim — viva structure point 128.
References
- [1]Latronico N, Bolton CF Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis Lancet Neurol, 2011.PMID 21939902
- [2]Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G Clinical review: Critical illness polyneuropathy and myopathy Crit Care, 2008.PMID 19040777
- [3]Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial Lancet, 2009.PMID 19446324
- [4]Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness JAMA, 2013.PMID 24108501
- [5]Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome N Engl J Med, 2011.PMID 21470008
- [6]Nordon-Craft A, Moss M, Quan D, Schenkman M Intensive care unit-acquired weakness: implications for physical therapist management Phys Ther, 2012.PMID 22282769